Mauna Kea Technologies SA (MKEAF)
- Business Wire
Mauna Kea Technologies Executes Agreement to Restructure its Existing Loan Agreement with the European Investment Bank
PARIS & BOSTON, April 24, 2024--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT) (Paris:ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced the execution of an agreement to restructure €21.3 million in outstanding debt obligations related to the Company’s finance contract with the European Investment Bank (EIB).
- Business Wire
Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
PARIS, April 04, 2024--Regulatory News: Mauna Kea Technologies (Paris:ALMKT):
- Business Wire
Mauna Kea Technologies Announces the Opening of the First Italian Center of Excellence for the Use of Cellvizio® to Identify and Treat Food Intolerance in Adults
PARIS & BOSTON, April 02, 2024--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT) (Paris:ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced the opening of the first Italian Center of Excellence for the use of Cellvizio to identify and treat food intolerances in adult patients suffering from Irritable Bowel Syndrome (IBS). The Cellvizio Food Intolerance Test (C-FIT) is now performed by Dr. Al
